YERVOY®(ipilimumab) Receives Marketing Authorisation for First-Line Treatment of Adult Patients with Advanced Melanoma in Europe

Paris, France (ots/PRNewswire) -

Yervoy, an innovative immuno-oncology therapy that has
demonstrated durable long-term survival in some patients,[1],[2] is
now approved for use in previously-untreated patients

Bristol-Myers Squibb today announced that the European Commission
(EC) has approved YERVOY(R) (ipilimumab) for the first-line treatment
of adult patients with advanced (unresectable or metastatic)
melanoma.[3] When initially approved in Europe in July 2011 for the
treatment of adult patients with previously-treated advanced
melanoma, ipilimumab represented the first major treatment advance in
this disease in more than 30 years, providing the first overall
survival benefit ever seen in the treatment of metastatic melanoma in
a phase III study.[1]

"This first-line approval of ipilimumab is important news for the
many people with advanced melanoma across Europe who have not
received prior treatment. Despite some advances in the first-line
treatment of advanced melanoma, for many patients there remains a
high unmet need for improved survival outcomes," commented Ron
Cooper, President, Bristol-Myers Squibb Europe. "The granting of this
licence extension underscores the belief in the therapeutic potential
of treatments like ipilimumab, which is the first approved therapy
from our immuno-oncology pipeline. At Bristol-Myers Squibb, we are
committed to the research and development of immuno-oncology, a
rapidly evolving and innovative treatment modality that harnesses the
natural capabilities of a patient's own immune system to fight
cancer."

Historically, the median life expectancy for patients with
metastatic melanoma, one of the most aggressive forms of skin cancer,
was just 6 to 9 months.[4]

"Ipilimumab is currently the only treatment for advanced melanoma
that has demonstrated durable long-term survival in pretreated
melanoma, in a randomised phase III trial.[2] With today's approval,
we may now be able to offer this innovative immuno-oncology therapy
to our advanced melanoma patients earlier in the course of their
treatment," said Professor Dirk Schadendorf, University Hospital
Essen, Germany.

The recommended treatment regimen of YERVOY is 3 mg/kg
administered intravenously over a 90-minute period every 3 weeks for
a total of 4 doses.[5] The types of adverse events attributed to
ipilimumab are generally mechanism (immune-) based and are managed
using protocol-specific guidelines.[2], [5],[6]Immune-related adverse
reactions, which can be severe or life-threatening, may involve the
gastrointestinal, liver, skin, nervous, endocrine, or other organ
systems. [2],[5] The safety profile of ipilimumab 3 mg/kg in
chemotherapy-naive patients pooled across phase II/III clinical
trials (N= 75) and in treatment naïve patients in a retrospective
observational study (N= 120) was similar to that in
previously-treated advanced melanoma.[5],[7]

The extension of the Marketing Authorisation was supported by data
derived from phase 2 and 3 studies conducted in advanced melanoma
patients, as well as from two retrospective observational studies in
first-line advanced melanoma patients who were treated with
ipilimumab 3mg/kg monotherapy.[3],[7],[8] These observational data
were presented at the European Cancer Congress (27 September - 1
October 2013). Overall survival (OS) of ipilimumab 3 mg/kg
monotherapy in chemotherapy-naive patients pooled across phase 2 and
3 clinical trials (N= 78; randomised) and in treatment-naive patients
in two retrospective observational studies (N= 120 and N= 61) were
generally consistent.[3],[7],[8] The estimated 1-year survival rates
were 59.5% (95% CI: 50.1 - 67.8) and 49.3% (95% CI: 35.6 - 61.6) in
the two retrospective observational studies.[3],[7],[8] The estimated
1-year and 2-year survival rates for chemotherapy-naive patients (N=
78) pooled across phase 2 and 3 clinical trials were 54.1% (95% CI:
42.5 - 65.6) and 32% (95% CI: 20.7 - 42.9), respectively.[3],[7],[8]

This extension of the indication for ipilimumab is applicable to
all 28 European Union member states as well as Iceland and Norway.
Bristol-Myers Squibb will now work closely with local health
authorities in these countries to expedite the availability of
ipilimumab for the first-line treatment of adult patients with
advanced melanoma, with the aim of addressing the significant unmet
need in treating this devastating disease.

About Metastatic Melanoma

Melanoma is a form of skin cancer characterised by the
uncontrolled growth of pigment-producing cells (melanocytes) located
in the skin.[9] Metastatic melanoma is one of the most aggressive
forms of the disease, and occurs when cancer spreads beyond the
surface of the skin to other organs, such as the lymph nodes, lungs,
brain or other areas of the body.[9],[10],[11] Some cancer cells can
actively evade surveillance by the immune system, allowing tumours to
survive. Historically, the median life expectancy for metastatic
melanoma patients was just 6 to 9 months.[4]

The incidence of melanoma in Europe has more than doubled over the
past 30 years.[12] Unlike most other solid tumours, melanoma affects
younger, middle aged people.[13] The median age at diagnosis for
melanoma is 57 and the median age at death from this disease is
67.[13] Melanoma is mostly curable when treated in its early
stages.[14]

About YERVOY(R)(ipilimumab)

Ipilimumab which is a recombinant, human monoclonal antibody,
blocks the cytotoxic T- lymphocyte antigen-4 (CTLA-4). CTLA-4 is a
negative regulator of T-cell activation. Ipilimumab binds to CTLA-4
and blocks the interaction of CTLA-4 with its ligands, CD80/CD86.
Blockade of CTLA-4 has been shown to augment T-cell activation and
proliferation. The mechanism of action of ipilimumab's effect in
patients with melanoma is indirect, possibly through T-cell mediated
anti-tumour immune responses.

In July 2011, the EU approved ipilimumab 3 mg/kg for the treatment
of adult patients with previously-treated unresectable or metastatic
melanoma.On 25 March 2011, the U.S. Food and Drug Administration
(FDA) approved ipilimumab 3 mg/kg for the treatment of patients with
unresectable (inoperable) or metastatic melanoma in the U.S,
regardless of line of therapy.

The value of ipilimumab as a second-line treatment in adults with
advanced (unresectable or metastatic) melanoma, has already been
recognised by many countries across Europe and has been made
accessible by local authorities to patients in Austria, Belgium,
Denmark, England, Finland, France, Germany, Ireland, Italy,
Luxembourg, Netherlands, Norway, Scotland, Spain, Sweden, Switzerland
and Wales.

For full Prescribing Information, please refer to the Yervoy
Summary of Product Characteristics.[5] For information on European
Commission decisions and annexes relating to ipilimumab, in all EU
languages, please visit http://ec.europa.eu/health/documents/communit
y-register/html/alfregister.htm.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines that
help patients prevail over serious diseases.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995 regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them, and
could cause actual outcomes and results to differ materially from
current expectations. No forward-looking statement can be guaranteed.
Forward-looking statements in this press release should be evaluated
together with the many uncertainties that affect Bristol-Myers
Squibb's business, particularly those identified in the cautionary
factors discussion in Bristol-Myers Squibb's Annual Report on Form
10-K for the year ended December 31, 2012, in our Quarterly Reports
on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers
Squibb undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.

References

1. Eggermont A and Robert C. New drugs in melanoma: it's a whole
new world. European J Cancer 2011; 47:2150-57

2. Hodi FS et al. Improved survival with ipilimumab in patients
with metastatic melanoma. N Engl J Med 2010; 363:711-23

3. European Commission - Community Register of Medicinal Products.
Updated October 2013. Available at: http://ec.europa.eu/health/docume
nts/community-register/html/h698.htm. Last accessed November 2013

4. Chin L et al. Malignant melanoma: Genetics and therapeutics in
the genomic era. Genes Dev 2006;20:2149-82.

5. YERVOY Summary of Product Characteristics 2013. Available at: h
ttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medi
cines/002213/human_med_001465.jsp&mid=WC0b01ac058001d124 . Last
accessed November 2013

6. Robert C et al. Ipilimumab plus Dacarbazine for Previously
Untreated Metastatic Melanoma. N Engl J Med 2011; 364:2517-26

7. Margolin K, Wong SL, Penrod JR, et al. Effectiveness and safety
of first-line ipilimumab (IPI) 3mg/kg therapy for advanced melanoma
(AM): Evidence from a U.S. multisite retrospective chart review.
Presented at: The European Cancer Congress 2013; September 27 -
October 1; Amsterdam, The Netherlands (P488)

8. Patt D, Wong SL, Juday T, et al. community-based, real-world,
study of treatment-naïve advanced melanoma (AM) patients treated with
3mg/kg ipilimumab (IPI) in the United States. Presented at: The
European Cancer Congress 2013; September 27 - October 1; Amsterdam,
The Netherlands (P497)

9. Skin Cancer Foundation. What is melanoma? Available at
http://www.skincancer.org/Melanoma. Last accessed November 2013

10. National Cancer Institute. Fact Sheet. Metastatic Cancer.
Available at:
http://www.cancer.gov/cancertopics/factsheet/Sites-Types/metastatic
Last accessed October 2013

11. American Cancer Society. What is metastatic cancer? Available
at: http://www.cancer.org/treatment/understandingyourdiagnosis/advanc
edcancer/advanced-cancer-what-is-metastatic . Last accessed November
2013

12. Garbe C et al. Melanoma epidemiology and trends. Clin Dermatol
2009;27:3-9.

13. Markovic SN et al. Malignant melanoma in the 21st century,
part 1: epidemiology, risk factors, screening, prevention, and
diagnosis. Mayo Clin Proc. 2007;82:364-38014. American Cancer
Society. Melanoma skin cancer. Can melanoma be found early? Available
at: http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/me
lanoma-skin-cancer-detection . Last accessed November 2013

ots Originaltext: Bristol-Myers Squibb GmbH & Co.KG aA
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media Contact: Elzbieta Zawislak, +48-608-55-55-89,
elzbieta.zawislak@bms.com